Contact us | Disclaimer | Sitemap ABOUT US CLINICAL STUDIES PRODUCTS TECHNOLOGY INVESTOR MEDIA Formulating for the Future of Transplant Patient Therapy Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here FEATURED EVENTS AUG 17, 2017 Q2 Report 2017 Investor Call Webcast Conference call at 3:00 pm CEST Please dial in 5-10 minutes prior to the start time using the number / Conference ID below. Denmark: +4532 71 16 59 United States of America: +1212 444 0412 United Kingdom: +44(0)20 3427 0503 Confirmation Code: 1870839 STOCK INFORMATION QUICK LINKS RELEASES PRODUCTS OUTLOOK CORPORATE GOVERNANCE OUR MANAGEMENT TEAM ANALYST COVERAGE RIGHTS ISSUE 2012 Veloxis Pharmaceuticals A/S | c/o Plesner Advokatpartnerselskab | Amerika Plads 37 | 2100 København Ø | Tel. +4570333300 | CVR-no. 26 52 77 67 | info@veloxis.com